Three congenital metabolic diseases in the Faeroe Islands;Tre medfødte metaboliske sygdomme på Faerøerne

Ugeskrift for Laeger

Volumn 168, Issue 7, 2006, Pages 667-670

  Joensen, Froöi ^a   Steuerwald, Elisabeth Ulrike ^a   Rasmussen, Niels H ^a  

^a Børneafdelingen ^*  (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CARNITINE; HOLOCARBOXYLASE SYNTHETASE; SYNTHETASE; UNCLASSIFIED DRUG;

CHILD CARE; COMMUNITY CARE; DISORDERS OF CARBOHYDRATE METABOLISM; GENE MUTATION; GLYCOGEN STORAGE DISEASE TYPE 3; HUMAN; INBORN ERROR OF METABOLISM; REVIEW; ADULT; CHILD; DENMARK; FEMALE; GENETICS; INCIDENCE; INFANT; MALE; MUTATION; NEWBORN; PRESCHOOL CHILD;

ADULT; CARNITINE; CHILD; CHILD, PRESCHOOL; DENMARK; FEMALE; GLYCOGEN STORAGE DISEASE TYPE III; HOLOCARBOXYLASE SYNTHETASE DEFICIENCY; HUMANS; INCIDENCE; INFANT; INFANT, NEWBORN; MALE; METABOLISM, INBORN ERRORS; MUTATION;

EID: 33644868146     PISSN: 00415782     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (14)

1. West JF. Faerøerne. En nation og den historie. København: Gyldendalske boghandel, Nordisk Forlag A/S, 1974:14-7.
2. Shen JJ, Chen YT. Molecular characterization af glycogen storage sygdom type III. Curr Mol Med 2002;2:167-75.
3. Parvari R, Moses S, Shen JJ et al. A single deletion in 3-prime coding region of glycogen-debraching enzyme is prevalent in glycogen storage syndrom type IIIA in population of North Africa Jewish children. Europ J Hum Gent 1997;5:266-70.
4. Moe PJ, Garatun-Tjeldstø E, Garatun-Tjeldstø O et al. Glycogen storage disease in Norway. Acta Pædiat Scand 1972;61:536-43.
5. Conn J, Wang P, Hauge M et al. Amylo-1,6-glucosidase defekt (glycogenosis type III) in Faroe Islands. Hum Hered 1975;25:115-26.
6. Santer R, Kinner M, Steuerwald U et al. Molecular genetic basis ad prevalence of glycogen storage disease type IIIA in Faroe Islands. Eur J Hum Genet 2001;9:388-91.
7. Lambonwah A-M, Olpin SE, Pollitt RJ et al. Novel OCTN2 mutations: no genotype-phenotype correlations: early carnitine therapy prevents cardiomyopathy. Am J Med Genet 2002;111:271-84.
8. Ganapathy ME, Huang W, Rajan DP et al. β-Lactam antibiotics as substrates for OCTN2, an organic cation / carnitine transporter. J Biol Chem 2000;275:1699-707.
9. Koizumi A, Nozaki JI, Ohura T et al. Genetic epidemiology of carnitine transporter OCTN2 gene in a Japanese population and phenotypic characterization in Japanese pedigrees with primary systemic carnitine deficiency. Hum Mol Genet 1999;8:2247-54.
10. Christensen E, Holm J, Hansen SH et al. Sudden infant death following pivampicillin treatment in a patient with carnitine transporter deficiency. J Inherit Metab Dis 2000;23(suppl 1):117.
11. Osá E, Simonsen H. Karnitintransportørdefekt hos to færøske børn. Ugeskr Læger 2004;166:4612-3.
12. Yang X, Aoki Y, Li X et al. Structure of human holocarboxylase synthethase gene and mutation spectrum of holocarboxylase synthethase deficiency. Hum Genet 2001;109:526-34.
13. Schwartz M, Sørensen N, Brandt NJ et al. High incidens af cystic fibrosis on the Faroe Islands: a molecular ad genealogical study. Hum Genet 1995;95:703-6.
14. Steig B, Juijn JA, Bull LN et al. Recurrent familiaer intrahepatisk kolestase på Færøerne. Ugeskr Læger 1999;161:4871-4.